search
Back to results

Evaluation of Mechanical Thrombectomy in Acute Ischemic Stroke Related to a Distal Arterial Occlusion (DISCOUNT)

Primary Purpose

Acute Ischemic Stroke (AIS) Related to a Distal Occlusion

Status
Recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Mechanical Thrombectomy
Best medical treatment alone
Sponsored by
Assistance Publique - Hôpitaux de Paris
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Acute Ischemic Stroke (AIS) Related to a Distal Occlusion focused on measuring Acute Ischemic Stroke, Distal occlusions, Mechanical Thrombectomy

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients aged ≥ 18 years
  • Delay between symptoms onset and expected groin puncture ≤ 6 h
  • Symptomatic occlusion as evaluated by a National Institute of Health Stroke Score (NIHSS) ≥ 5
  • Distal occlusion evaluated on CT angiography (CTA) or magnetic resonance imaging (MRI) and defined as an occlusion in one of the following segments:

    • Distal M2, above the mid-height of the insula
    • M3 segment
    • Posterior cerebral artery (PCA): P1, P2, P3 segments
    • Anterior cerebral artery (ACA): A1, A2, A3 segments
  • Written informed consent signed by the patient or the trustworthy person / family member / close relative, or inclusion in case of emergency and written informed consent will be signed by the patient (if needed by trustworthy person, family member or close relative) as soon as possible (article L1122-1-2 of the French Public Health Code)

Exclusion Criteria:

  • Pregnancy or breastfeeding woman
  • Contra-indication for femoral, radial or humeral arterial puncture
  • Tandem occlusion (i.e.: concomitant cervical and intra-cranial arterial occlusion)
  • Allergy to iodinated contrast media
  • Known renal insufficiency (confirmed by previous result of creatinine clearance < 30 ml/min)
  • Secondary distal occlusion (i.e., complicating a MT for a proximal occlusion, or any other endovascular intracranial procedure)
  • Aortic dissection
  • Asymptomatic or minor stroke (i.e.: NIHSS < 5)
  • Pretreatment mRS > 1 (pre-stroke)
  • Anticipated limitations for anesthesia
  • Participation in another trial (Jardé 1 and Jardé 2)
  • Absence of affiliation to National French social security system
  • Under legal protection measure (tutorship or curatorship) and patient deprived of freedom
  • A pre-existing hemorrhage in the brain tissue fed by the target vessel
  • Known hypersensitivity to nickel/titanium
  • Stenosis and/or with a stent proximal to the site of the thrombus which could preclude the retrieval of the stent retriever
  • Angiographic evidence of carotid dissection

Sites / Locations

  • Frédéric CLARENCONRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Mechanical thrombectomy

Active Comparator

Arm Description

Mechanical thrombectomy (using a stent retriever among the following:Trevo NXT ProVue Retriever, Catchview mini, pReset Lite, Tigertriever 13) in association with the best medical treatment (usual care)

Best medical treatment alone (usual care)

Outcomes

Primary Outcome Measures

Good clinical outcome (defined as a modified Rankin Scale [mRS] ≤ 2)
mRS of 0-2 (evaluated by an independent assessor blinded to the intervention received by the patient)

Secondary Outcome Measures

Recanalization of the occluded vessel
Evaluation of AOL (Arterial Occlusion Lesion scale) ≥ 2 on vascular brain imaging (magnetic resonance MR) or computed tomography (CT) angiography in patients belonging to both arms
Angiographic reperfusion in the intervention group
Use of the mTICI score (successful reperfusion: mTICI 2b-3) and the eTICI (extended thrombolysis in cerebral infarction) score (successful reperfusion: eTICI ≥ 2b67) on the control digital subtraction angiography (DSA)
Excellent Clinical outcome (defined as a modified Rankin Scale [mRS] ≤ 1)
mRS of 0-1 (evaluated by an independent assessor blinded to the intervention received by the patient)
Perforation rate
Defined as contrast material extravasation either on digital subtraction angiography [DSA] or control CT scan
Embolus migration in a new territory
evaluated on digital subtraction angiography [DSA]
Symptomatic intracranial hemorrhage
evaluated on CT-scan or MRI according to the ECASS II criteria
Subarachnoid hemorrhage
evaluated on CT-scan or MRI and define as the abnormal presence of blood within the subarachnoid space presence of blood within the subarachnoid space
Safety : incidence of adverse events
Reporting of all adverse events
Safety : incidence of serious adverse events
Reporting of all serious adverse events
Death rate
Mortality
Utility of the procedure
Incremental cost utility ratio
Cost effectiveness
Cost per additional survivor (health-economics analysis)

Full Information

First Posted
July 31, 2021
Last Updated
April 14, 2023
Sponsor
Assistance Publique - Hôpitaux de Paris
search

1. Study Identification

Unique Protocol Identification Number
NCT05030142
Brief Title
Evaluation of Mechanical Thrombectomy in Acute Ischemic Stroke Related to a Distal Arterial Occlusion
Acronym
DISCOUNT
Official Title
Evaluation of Mechanical Thrombectomy in Acute Ischemic Stroke Related to a Distal Arterial Occlusion: a Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
April 2023
Overall Recruitment Status
Recruiting
Study Start Date
November 14, 2021 (Actual)
Primary Completion Date
February 14, 2024 (Anticipated)
Study Completion Date
February 14, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Assistance Publique - Hôpitaux de Paris

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Mechanical thrombectomy (MT) has shown its effectiveness for the treatment of acute ischemic stroke (AIS) related to large vessel occlusion and rapidly became a cornerstone in the management of these patients. No strong evidence is available on the benefit of MT in AIS related to more distal occlusions. Some previous observational studies suggested a possible benefit but most of them were single-centre and retrospective studies providing a very low level of evidence. To date, no randomized controlled trial has been conducted in this indication, which represents 10% to 20% of all AIS involving intracranial vessel occlusions. This research is a multicenter open randomized controlled trial with two parallel groups : best medical treatment alone VS mechanical trombectomy + best medical treatment.
Detailed Description
The main objective of this trial is to assess the efficacy of mechanical thrombectomy in addition to the best medical treatment as compared to the best medical treatment alone in AIS related to a distal intracranial artery occlusion. The medical device used will be a stent retriever among : Trevor NXT ProVue Retriever ; Catchview mini ; pReset Lite ; Tigertriever13, and the medical treatment used will depend on the stroke's etiology and will consist of IV trhombolysis or tenecteplase or antiplatelet therapy or anticoagulant therapy ... The main inclusion criteria are : 1) patients aged ≥ 18 years ; 2) Delay between symptoms onset and expected groin puncture ≤ 6h ; 3) Symptomatic occlusion as evaluated by a National Institute of Health Stroke Score (NIHSS) ≥ 5 ; 4) Distal occlusion evaluated on CT angiography (CTA) or magnetic resonance imaging (MRI) and defined as an occlusion in one of the following segments : a-Distal M2, above the mid-height of the insula, b-M3 segment, c-Posterior cerebral artery (PCA) = P1, P2 or P3 segment, d-Anterior cerebral artery (ACA) : A1, A2 or A3 segment ; 5) Written informed consent signed by the patient or the trustworthy person / family member / close relative, or inclusion in case of emergency and written informed consent will be signed by the patient (if needed by trustworthy person, family member or close relative) as soon as possible (article L1122-1-2 of the French Public Health Code). The secondary objectives and endpoints are to evaluate the : 1) Success of the procedure defined as recanalization of the occluded vessel, evaluated on the AOL (Arterial Occlusion Lesion) score within 48 hours ; 2) Excellent clinical outcome (defined as a modified Rankin scale [mRS]≤1) at 3 months ; 3) Safety with reporting of all adverse and serious adverse events with a particular attention to perforation rate, embolus migration in a new territory and symptomatic hemorrhagic complications ; 4) Death rate up to 3 months ; 5) Cost effectiveness and utility of the procedure. The study will also evaluate the rate of angiographic reperfusion in the intervention group on the final angiogram at the end of the MT (which is part of the intervention) using the modified thrombolysis in cerebral infarction (mTICI) (2B-3) and the eTICI.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acute Ischemic Stroke (AIS) Related to a Distal Occlusion
Keywords
Acute Ischemic Stroke, Distal occlusions, Mechanical Thrombectomy

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
488 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Mechanical thrombectomy
Arm Type
Experimental
Arm Description
Mechanical thrombectomy (using a stent retriever among the following:Trevo NXT ProVue Retriever, Catchview mini, pReset Lite, Tigertriever 13) in association with the best medical treatment (usual care)
Arm Title
Active Comparator
Arm Type
Active Comparator
Arm Description
Best medical treatment alone (usual care)
Intervention Type
Procedure
Intervention Name(s)
Mechanical Thrombectomy
Other Intervention Name(s)
Experimental group
Intervention Description
Mechanical thrombectomy (using a stent retriever among the following:Trevo NXT ProVue Retriever, Catchview mini, pReset Lite, Tigertriever 13) in association with the best medical treatment (usual care)
Intervention Type
Drug
Intervention Name(s)
Best medical treatment alone
Other Intervention Name(s)
Control group
Intervention Description
Best medical treatment alone (usual care)
Primary Outcome Measure Information:
Title
Good clinical outcome (defined as a modified Rankin Scale [mRS] ≤ 2)
Description
mRS of 0-2 (evaluated by an independent assessor blinded to the intervention received by the patient)
Time Frame
At 3 months
Secondary Outcome Measure Information:
Title
Recanalization of the occluded vessel
Description
Evaluation of AOL (Arterial Occlusion Lesion scale) ≥ 2 on vascular brain imaging (magnetic resonance MR) or computed tomography (CT) angiography in patients belonging to both arms
Time Frame
48 hours after the mechanical thrombectomy
Title
Angiographic reperfusion in the intervention group
Description
Use of the mTICI score (successful reperfusion: mTICI 2b-3) and the eTICI (extended thrombolysis in cerebral infarction) score (successful reperfusion: eTICI ≥ 2b67) on the control digital subtraction angiography (DSA)
Time Frame
End of the mechanical thrombectomy procedure
Title
Excellent Clinical outcome (defined as a modified Rankin Scale [mRS] ≤ 1)
Description
mRS of 0-1 (evaluated by an independent assessor blinded to the intervention received by the patient)
Time Frame
At 3 months
Title
Perforation rate
Description
Defined as contrast material extravasation either on digital subtraction angiography [DSA] or control CT scan
Time Frame
End of mechanical thrombectomy procedure
Title
Embolus migration in a new territory
Description
evaluated on digital subtraction angiography [DSA]
Time Frame
End of mechanical thrombectomy procedure
Title
Symptomatic intracranial hemorrhage
Description
evaluated on CT-scan or MRI according to the ECASS II criteria
Time Frame
within 7 days
Title
Subarachnoid hemorrhage
Description
evaluated on CT-scan or MRI and define as the abnormal presence of blood within the subarachnoid space presence of blood within the subarachnoid space
Time Frame
within 48 hours
Title
Safety : incidence of adverse events
Description
Reporting of all adverse events
Time Frame
At 3 months
Title
Safety : incidence of serious adverse events
Description
Reporting of all serious adverse events
Time Frame
At 3 months
Title
Death rate
Description
Mortality
Time Frame
At 3 months
Title
Utility of the procedure
Description
Incremental cost utility ratio
Time Frame
At 3 months
Title
Cost effectiveness
Description
Cost per additional survivor (health-economics analysis)
Time Frame
At 3 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients aged ≥ 18 years Delay between symptoms onset and expected groin puncture ≤ 6 h Symptomatic occlusion as evaluated by a National Institute of Health Stroke Score (NIHSS) ≥ 5 Distal occlusion evaluated on CT angiography (CTA) or magnetic resonance imaging (MRI) and defined as an occlusion in one of the following segments: Distal M2, above the mid-height of the insula M3 segment Posterior cerebral artery (PCA): P1, P2, P3 segments Anterior cerebral artery (ACA): A1, A2, A3 segments Written informed consent signed by the patient or the trustworthy person / family member / close relative, or inclusion in case of emergency and written informed consent will be signed by the patient (if needed by trustworthy person, family member or close relative) as soon as possible (article L1122-1-2 of the French Public Health Code) Exclusion Criteria: Pregnancy or breastfeeding woman Contra-indication for femoral, radial or humeral arterial puncture Tandem occlusion (i.e.: concomitant cervical and intra-cranial arterial occlusion) Allergy to iodinated contrast media Known renal insufficiency (confirmed by previous result of creatinine clearance < 30 ml/min) Secondary distal occlusion (i.e., complicating a MT for a proximal occlusion, or any other endovascular intracranial procedure) Aortic dissection Asymptomatic or minor stroke (i.e.: NIHSS < 5) Pretreatment mRS > 1 (pre-stroke) Anticipated limitations for anesthesia Participation in another trial (Jardé 1 and Jardé 2) Absence of affiliation to National French social security system Under legal protection measure (tutorship or curatorship) and patient deprived of freedom A pre-existing hemorrhage in the brain tissue fed by the target vessel Known hypersensitivity to nickel/titanium Stenosis and/or with a stent proximal to the site of the thrombus which could preclude the retrieval of the stent retriever Angiographic evidence of carotid dissection
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Frédéric Clarençon, Professor
Phone
+ 33 1 42 16 35 43
Email
frederic.clarencon@aphp.fr
First Name & Middle Initial & Last Name or Official Title & Degree
Anne Radenne, Manager
Phone
+ 33 1 42 16 16 99
Email
anne.radenne@aphp.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Frédéric Clarençon, Professor
Organizational Affiliation
APHP
Official's Role
Principal Investigator
Facility Information:
Facility Name
Frédéric CLARENCON
City
Paris
ZIP/Postal Code
75013
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Anne RADENNE
Phone
0142161699

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Data are available upon reasonable request. The procedures carried out with the French data privacy authority (CNIL, Commission nationale de l'informatique et des libertés) do not provide for the transmission of the database, nor do the information and consent documents signed by the patients. Consultation by the editorial board or interested researchers of individual participant data that underlie the results reported in the article after deidentification may nevertheless be considered, subject to prior determination of the terms and conditions of such consultation and in respect for compliance with the applicable regulations.
IPD Sharing Time Frame
Beginning 3 months and ending 3 years following article publication. Requests out of these time frame can also be submitted to the sponsor
IPD Sharing Access Criteria
Researchers who provide a methodologically sound proposal.

Learn more about this trial

Evaluation of Mechanical Thrombectomy in Acute Ischemic Stroke Related to a Distal Arterial Occlusion

We'll reach out to this number within 24 hrs